Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.